First Trust Advisors LP Invests $6.86 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

First Trust Advisors LP acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 128,062 shares of the company's stock, valued at approximately $6,856,000. First Trust Advisors LP owned about 0.24% of Janux Therapeutics as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after buying an additional 442 shares during the period. Avanza Fonder AB purchased a new position in Janux Therapeutics in the fourth quarter worth $139,000. Meeder Asset Management Inc. bought a new position in Janux Therapeutics in the fourth quarter valued at $159,000. Chicago Capital LLC bought a new stake in Janux Therapeutics during the fourth quarter worth about $230,000. Finally, Cerity Partners LLC purchased a new position in shares of Janux Therapeutics in the 4th quarter worth about $239,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $3,473,658.31. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was purchased at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the acquisition, the director now owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. This represents a 3.67 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 13,335 shares of company stock valued at $454,959. Corporate insiders own 29.40% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Wedbush restated an "outperform" rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. Scotiabank reduced their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. Finally, William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $95.25.

Janux Therapeutics Stock Up 2.6 %

Shares of Janux Therapeutics stock traded up $0.83 during trading on Friday, reaching $32.88. 825,257 shares of the stock were exchanged, compared to its average volume of 848,137. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -28.10 and a beta of 3.27. Janux Therapeutics, Inc. has a 1 year low of $22.52 and a 1 year high of $71.71. The stock's fifty day moving average is $29.80 and its 200 day moving average is $42.57.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.